Ribociclib (LEE011) Rollover Study for Continued Access
- Patient is currently enrolled in an eligible Novartis-sponsored study and receiving ribociclib (LEE011) as single agent or in combination with other investigational treatment.
- Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator.
- Patient has been permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason.
- Patients who do not meet parent protocol criteria to continue study treatment.
Trial Phase Phase II
Trial Type Treatment
Novartis Pharmaceuticals Corporation
- Primary ID CLEE011X2X01B
- Secondary IDs NCI-2017-00789
- Clinicaltrials.gov ID NCT02934568